Cooper Financial Group Purchases New Holdings in Astrazeneca Plc $AZN

Cooper Financial Group acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the second quarter, HoldingsChannel reports. The fund acquired 6,342 shares of the company’s stock, valued at approximately $1,203,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Triumph Capital Management bought a new stake in shares of Astrazeneca in the third quarter worth $25,000. MV Capital Management Inc. bought a new position in Astrazeneca during the 4th quarter valued at $26,000. Mascoma Wealth Management LLC acquired a new position in Astrazeneca during the 1st quarter worth $26,000. Roxbury Financial LLC bought a new stake in shares of Astrazeneca in the 2nd quarter worth about $29,000. Finally, Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca in the 4th quarter worth about $30,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Up 0.1%

AZN stock opened at $161.28 on Friday. The firm has a market cap of $250.12 billion, a PE ratio of 24.11, a P/E/G ratio of 1.39 and a beta of 0.26. Astrazeneca Plc has a 12 month low of $145.79 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. The firm has a 50 day simple moving average of $176.34 and a 200 day simple moving average of $187.11.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.17 earnings per share. Equities research analysts forecast that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Finally, UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.